Onconetix (NASDAQ:ONCO) Shares Up 4.2% – What’s Next?

Onconetix, Inc. (NASDAQ:ONCO)’s share price was up 4.2% on Thursday . The company traded as high as $0.13 and last traded at $0.13. Approximately 3,474,206 shares changed hands during trading, an increase of 28% from the average daily volume of 2,706,624 shares. The stock had previously closed at $0.13.

Onconetix Stock Performance

The stock’s 50-day moving average price is $0.42 and its two-hundred day moving average price is $1.89.

Institutional Trading of Onconetix

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Millennium Management LLC purchased a new stake in shares of Onconetix in the 4th quarter worth approximately $25,000. Geode Capital Management LLC purchased a new stake in shares of Onconetix in the fourth quarter worth $35,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Onconetix by 83.8% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 562,691 shares of the company’s stock valued at $2,926,000 after purchasing an additional 256,612 shares in the last quarter. Institutional investors own 23.89% of the company’s stock.

About Onconetix

Onconetix, Inc, a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer.